mass cytometry
Standard BioTools Q1 Revenues Fall 19 Percent
In Q1 the company formerly known as Fluidigm completed a strategic evaluation process and closed a $250 million capital infusion from Casdin Capital and Viking Global Investors.
Single-Cell Proteomic Analysis Points to Role of Rare Cell Populations in Localized Prostate Cancer
Some rare cell populations identified have been linked to aggressive or metastatic disease.
New Epigenomic Biomarker Could Predict CAR T-Cell Therapy Resistance in Advanced Childhood Leukemia
Premium
At AACR, researchers described how pediatric ALL patients who don't respond to anti-CD19 CAR T-cell therapy have cancers with a unique, stem cell-like epigenome.
Fluidigm Appeal in IonPath Patent Infringement Battle Voluntarily Dismissed
The verdict seemingly closes a lawsuit filed by Fluidigm against IonPath in 2019 for allegedly infringing patents covering Fluidigm's mass cytometry technology.
Fluidigm Q2 Revenues Grow 19 Percent
The firm noted that its base product and service revenue (excluding COVID-19 testing) increased 33 percent year over year to $26.9 million.
Feb 11, 2021
Feb 10, 2021
Aug 4, 2020
Fluidigm, De Novo Software Ink Distribution Deal
May 7, 2020
Fluidigm Q1 Revenues Fall 8 Percent
Feb 10, 2020
Fluidigm Reports Flat Q4 Revenues
Jan 14, 2020
Fluidigm Anticipates Flat Q4 Revenues
May 3, 2019